CIK 0001781174
- Emerging growth company
Acrivon Therapeutics, Inc.
Sign in to watch- Ticker
- ACRV
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 825125532
- Phone
- +1 617-207-8979
- Business address
- 480 ARSENAL WAY, SUITE 100, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $32,498
- in 3 filings
Net −$32,498. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-11-14 | Masson Kristina EVP - Business Operations | Grant or award · Stock Option (Right to Buy) | +80,120 | 80,120 | ||
| 2022-11-14 | Masson Kristina EVP - Business Operations | Grant or award · Stock Option (Right to Buy) | +180,269 | 180,269 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award | +934,731 | 1,806,588 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award | +503,419 | 2,310,007 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award | +60,090 | 2,370,097 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award | +26,707 | 320,705 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +180,269 | 180,269 | ||
| 2022-11-14 | Blume-Jensen Peter President and CEO | Grant or award · Stock Option (Right to Buy) | +80,120 | 80,120 | ||
| 2022-11-14 | RA CAPITAL MANAGEMENT, L.P. Director | Grant or award · Stock Option (Right to Buy) | +35,235 | 35,235 |
Page 12 of 12 · 229 trades